Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Q4 2025 value amounting to $218.9 million.

  • Arrowhead Pharmaceuticals' Receivables - Net rose 865484.0% to $218.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $218.9 million, marking a year-over-year increase of 865484.0%. This contributed to the annual value of $6.8 million for FY2025, which is N/A changed from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Receivables - Net of $218.9 million as of Q4 2025, which was up 865484.0% from $6.8 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Receivables - Net peaked at $218.9 million during Q4 2025, and registered a low of $150000.0 during Q4 2021.
  • For the 5-year period, Arrowhead Pharmaceuticals' Receivables - Net averaged around $24.4 million, with its median value being $2.4 million (2025).
  • In the last 5 years, Arrowhead Pharmaceuticals' Receivables - Net tumbled by 9833.37% in 2021 and then soared by 2627866.67% in 2022.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Receivables - Net stood at $150000.0 in 2021, then surged by 26278.67% to $39.6 million in 2022, then tumbled by 96.11% to $1.5 million in 2023, then surged by 62.44% to $2.5 million in 2024, then surged by 8654.84% to $218.9 million in 2025.
  • Its Receivables - Net was $218.9 million in Q4 2025, compared to $6.8 million in Q3 2025 and $9.7 million in Q2 2025.